Shengfang Jin

Shengfang Jin has extensive experience in the biotechnology and pharmaceutical industry, holding various leadership positions in companies such as Agios Pharmaceuticals, Editas Medicine, and Ensem Therapeutics. With a strong background in molecular biology and genetics, Jin has led teams in the discovery and development of novel drugs for cancer, rare genetic disorders, and other serious diseases. Jin's expertise in genome editing technologies such as CRISPR/Cas9 and CRISPR/Cpf1 has contributed to the advancement of precision genomic medicine. Additionally, Jin has a solid foundation in cell biology and assay development, as well as experience in gene therapy research. Overall, Jin is a seasoned professional with a strong track record of driving innovation in the field of biotechnology.